Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Anderson, William F ^a   Rosenberg, Philip S ^a   Katki, Hormuzd A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

AGE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER REGISTRY; CLINICAL TRIAL (TOPIC); EDITORIAL; EPITHELIUM CELL; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; LONG TERM SURVIVAL; OROPHARYNX CANCER; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER; WART VIRUS; BIOSYNTHESIS; BREAST TUMOR; CLASSIFICATION; FEMALE; NOTE;

BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84905166485     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju093     Document Type: Editorial

References (30)

1. Clemmesen J. Carcinoma of the breast. Br J Radiol. 1948;21(252):583-590.
2. Lilienfeld AM, Johnson EA. The age distribution in female breast and genital cancers. Cancer. 1955;8(5):875-882.
3. De Waard F, De Laive JWJ, Baanders-van Halewijn EA. On bimodal age distribution of mammary carcinoma. Br J Cancer. 1960;14:437-448.
4. Moolgavkar SH, Lee JA, Hade RD. Comparison of age-specific mortality from breast cancer in males in the United States and Japan. J Natl Cancer Inst. 1978;60(6):1223-1225.
5. Anderson WF, Matsuno RK. Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst. 2006;98(14):948-951.
6. Anderson E, Reed SC, Huseby RA, Oliver C P. Possible relationship between menopause and age at onset of breast cancer. Cancer. 1950;3:410-414.
7. Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev. 1993;15(1):209-219.
8. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76(1):27-36.
9. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cnacer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;XX(XX):XXX-XXX.
10. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
11. Curtis C, Shah S P, Chin SF, et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
12. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-10874.
13. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418-8423.
14. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26(14):2373-2378.
15. Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2012;104(14):1094-1101.
16. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353(16):1652-1654.
17. Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.
18. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672.
20. Brinton LA, Benichou J, Gammon MD, Brogan DR, Coates R, Schoenberg JB. Ethnicity and variation in breast cancer incidence. Int J Cancer. 1997;73(3):349-355.
21. Gray GE, Henderson BE, Pike MC. Changing ratio of breast cancer incidence rates with age of black females compared with white females in the United States. J Natl Cancer Inst. 1980;64(3):461-463.
22. Anderson WF, Katki HA, Rosenberg PS. Breast cancer incidence in the United States: current and future trends. J Natl Cancer Inst. 2011;103(18):1397-1402.
23. Howlader N, Noone AM, Yu M, Cronin KA. Use of Imputed Population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am J Epidemiol. 2012;176(4):347-356.
24. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707- 712.
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-182.
26. Henderson IC, Patek AJ. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998;52(1-3):261-288.
27. Goodman MT, Hernandez BY, Hewitt S, et al. Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol. 2005;36(7):812-820.
28. Anderson WF, Luo S, Chatterjee N, et al. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat. 2009;113(1):189-196.
29. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-4301.
30. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London: Nuffield Provincial Hospitals Trust; 1972.